Advancements in molecular biology technology allowed the development of promising biomarkers, such as Peripheral blood gene expression profiling (GEP) and cell-free DNA (cfDNA), for minimally invasive characterisation of allograft rejection.
The use of circulating GEP and cfDNA may offer advantages over invasive tissue biopsy as a quantitative measure for detection of transplant rejection and immunosuppression optimisation. However, there is no standard recognition of the usage of this new technology.
The objectives of this project are
Kidney
Heart & Lung
Sean Agbor-EnohRead Profile
Marisa Crespo LeiroRead Profile
Kiran KhushRead ProfileLiver
Marina BerenguerRead Profile
Eleonora De MartinRead Profile
Josh LevitskyRead Profile
Valeria MasRead ProfileThis project is possible thanks to the kind support of Eurofins, Natera, Thermofisher